Long-term Safety of Guselkumab (TREMFYA (R)) in Patients with Active Psoriatic Arthritis: Pooled Results from 3 Randomized Clinical Trials Through up to 2 Years

Rahman, P, Ritchlin, C, Mease, P et al. (11 more authors) (2021) Long-term Safety of Guselkumab (TREMFYA (R)) in Patients with Active Psoriatic Arthritis: Pooled Results from 3 Randomized Clinical Trials Through up to 2 Years. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Metadata

Authors/Creators:
Dates:
  • Published: September 2021
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 05 Aug 2022 12:26
Last Modified: 05 Aug 2022 12:26
Status: Published
Identification Number: https://doi.org/10.1002/art.41966
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)